Compare Natera Inc. Common Stock (NTRA) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Natera Inc. Common Stock trades at $391.06 (market cap $57.03B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.77 (market cap $7.97B). The key difference: Natera Inc. Common Stock is far larger — about 7.2× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is more actively traded (3,246,731 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| NTRA | PDBC | |
|---|---|---|
Market Cap | $57.03B | $7.97B |
Volume | 1,131,157 | 3,246,731 |
Sector | Health | — |
52-Week High | $425.64 | $20.10 |
52-Week Low | $179.42 | $13.19 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $19.98, up 0.6% on the day, with a strong bullish technical signal from moving averages. The ETF has delivered robust performance, rising 45.66% year-to-date through Q3 2026, driven by gains in energy and agricultural commodities amid geopolitical tensions. Institutional interest is growing, with several advisors increasing positions recently, though short interest also surged significantly in September.
The outlook for PDBC remains positive given ongoing commodity strength and defensive investor shifts, but risks include heightened short interest and geopolitical volatility that could pressure returns. Investors should weigh the ETF's momentum against potential pullbacks from overbought conditions and external shocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
